Abstract
Pseudoprogression (PSP) is an initial increase in the size of the primary tumor or the appearance of the new lesions followed by a distinct decrease in tumor burden. Herein, we aimed to evaluate the effect of PSP on treatment response in patients with advanced non-small cell lung cancer (NSCLC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
